Cyclacel Pharma, Drew Industries, Stoneridge Among Hot Stocks Feb 13th
Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC): Cyclacel Pharmaceuticals announced new topline response data from an ongoing, multicenter, Phase 2 randomized trial of oral sapacitabine capsules, a novel nucleoside analogue, in older patients with myelodysplastic syndromes after treatment failure of hypomethylating agents, such as azacitidine and/or decitabine. Eight patients responded with 2 complete remissions, 2 complete remissions with incomplete platelet count recovery and 4 major hematological improvements of platelet counts or neutrophils. More than 50% of the patients are still alive and longer follow-up is needed to assess 1-year survival and overall survival. Shares of Cyclacel Pharmaceuticals Inc. are trading 16.67% higher today.
Drew Industries, Inc. (NYSE:DW): Manufactured housing sales were $29M vs. $20M in Q4 of 2010. Shares of Drew Industries, Inc. are trading 2.9% higher today.
Stoneridge, Inc. (NYSE:SRI): Reports Q4 revenue $186.0M, up 15.9% from $160.5M in Q4 of 2010. Consensus $194.60M. The Q4 net income increase was primarily due to a $65.4M pretax gain and a $42.5M after-tax gain or $1.72 per share recognized in conjunction with Stoneridge’s previously announced purchase of additional ownership in its Brazil-based PST joint venture. Shares of Stoneridge, Inc. are trading 2.82% lower today.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.
To contact the reporter on this story: Derek Hoffman at firstname.lastname@example.org
To contact the editor responsible for this story: Damien Hoffman at email@example.com